
Acalabrutinib 100 mg (Acaya) is a targeted anticancer medicine used to treat certain blood cancers, including chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). It works by blocking signals that help cancer cells grow and survive, slowing disease progression and improving treatment outcomes.
| Generic name | Acalabrutinib |
| Strength | 100 mg |
| Manufacturer | ZYDUS |
| Package size | 1 Bottle of 60 Capsules |
| Used for | Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL), and Mantle Cell Lymphoma (MCL) |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Acalabrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor. It works by blocking the BTK protein, which plays a key role in the growth and survival of certain cancerous B cells. By inhibiting this protein, Acalabrutinib helps stop cancer cells from multiplying and promotes their destruction.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.